Jitka Veselá

<i>TP53</i> mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

Monika Beličková, Jitka Veselá, Anna Jonášová et al. · Oncotarget · 2016 · 57 citations · Full text

Medicine, Genetics, Hematology +16

Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome

Andrea Hruštincová, Zdeněk Krejčík, Dávid Kundrát et al. · Cells · 2020 · 41 citations · Full text

Medicine, Hematology, Molecular Medicine +15

Aflatoxin and encephalopathy with fatty degeneration of viscera (Reye).

I Dvorăcková, Kusák, D Veselý et al. · PubMed · 1977 · 30 citations

Medicine, Pathology, Pediatrics +15

LncRNA Profiling Reveals That the Deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 Is Associated with Higher-Risk Myelodysplastic Syndrome

Katarína Szikszai, Zdeněk Krejčík, Nikoleta Loudová et al. · Cancers · 2020 · 26 citations · Full text

Life Sciences, Hematology, Molecular Biology +15

RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS

Monika Kaisrlikova, Jitka Veselá, Dávid Kundrát et al. · Leukemia · 2022 · 26 citations · Full text

Medicine, Molecular Genetics, Oncology +13